{
    "clinical_study": {
        "@rank": "51990", 
        "arm_group": [
            {
                "arm_group_label": "CTO and Bevacizumab (Phase 1)", 
                "arm_group_type": "Experimental", 
                "description": "The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab"
            }, 
            {
                "arm_group_label": "Phase 2: CTO alone (Phase 2)", 
                "arm_group_type": "Experimental", 
                "description": "The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study."
            }, 
            {
                "arm_group_label": "CTO and Bevacizumab (Phase 2)", 
                "arm_group_type": "Experimental", 
                "description": "The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of the study are to determine the maximum tolerated dose (MTD) of\n      Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among\n      patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed\n      bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO\n      grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus\n      bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2)."
        }, 
        "brief_title": "Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure", 
        "condition": "Malignant Glioma (WHO Grade III or IV)", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "detailed_description": {
            "textblock": "In Phase 1 of the study, we will conduct a dose-escalation study of the combination of CTO\n      with the standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO\n      Grade III or IV) that have previously failed bevacizumab. All patients will have also\n      received standard treatment with radiation therapy and temozolomide prior to enrollment on\n      study.\n\n      The Phase 2 portion of this study will investigate two novel treatment regimens\n      sequentially.  Each regimen will include 25 patients with recurrent WHO grade IV malignant\n      glioma who have been treated in the past with standard radiation therapy, temozolomide, and\n      bevacizumab. All patients must have failed therapy while on bevacizumab.  Subjects in the\n      first treatment regimen will receive CTO alone and subjects in the second treatment regimen\n      will receive the combination of CTO and bevacizumab together."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Phase 1 portion: Patients must have recurrent histologically confirmed diagnosis of\n             World Health Organization (WHO) grade III or IV malignant glioma with no more than 3\n             prior progressions\n\n          -  Phase 2 portion: Patients must have recurrent histologically confirmed diagnosis of\n             WHO grade IV malignant glioma (glioblastoma or gliosarcoma) with no more than 3 prior\n             progressions.\n\n          -  Must have had a least 1 prior progression on a bevacizumab-containing regimen\n\n          -  Age greater than or equal to 18 years\n\n          -  Karnofsky \u2265 60%\n\n          -  Bi-dimensionally measurable disease, as assessed by magnetic resonance imaging based\n             on The Revised Assessment in Neuro-Oncology (RANO) criteria\n\n          -  Absolute neutrophil count (ANC) \u22651000 cells/\u00b5l, Platelets \u2265 100,000 cells/\u00b5l (without\n             transfusion within 14 days before enrollment)\n\n          -  Adequate renal function as indicated by the following: Serum creatinine < 1.25 times\n             upper limit of normal (ULN) or calculated creatinine clearance \u2265 50 ml/min; Urine\n             dipstick for proteinuria < 2+ unless a 24-hour urine protein <1 g of protein is\n             demonstrated\n\n          -  Prothrombin time (PT) \u2264 1.5 and activated partial thromboplastin time (aPTT) \u2264 1.5 x\n             ULN within 14 days prior to first study treatment for patients not receiving\n             anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted\n             as long as the PT or  aPTT is within therapeutic limits (according to the medical\n             standard of the enrolling institution) and the patient has been on a stable dose of\n             anticoagulants for at least two weeks prior to the first study treatment.\n\n          -  For patients on corticosteroids, they must be on a stable dose for 7 days prior to\n             anticipated start of study drug, and the dose should not be escalated over entry dose\n             level, if clinically possible\n\n          -  Signed informed consent approved by the Institutional Review Board\n\n          -  No evidence of > grade 1 active central nervous system (CNS) hemorrhage on the\n             baseline magnetic resonance imaging (MRI) or computed tomography (CT) scan\n\n          -  Female patients must not be pregnant or breast-feeding.  Female patients of\n             childbearing potential (defined as < 2 years after last menstruation or not\n             surgically sterile) must use a highly effective contraceptive method (allowed methods\n             of birth control, [i.e. with a failure rate of < 1% per year] are implants,\n             injectables, combined oral contraceptives, intra-uterine device (IUD) (only\n             hormonal), sexual abstinence or vasectomized partner) during the trial and for a\n             period of > 6 months following the last administration of trial drug(s).  Female\n             patients with an intact uterus (unless amenorrhea for the last 24 months) must have a\n             negative serum pregnancy test within 48 hours prior to first study treatment.\n\n          -  Fertile male patients must agree to use a highly effective contraceptive method\n             (allowed methods of birth control [i.e. with a failure rate of < 1% per year] include\n             a female partner using implants, injectables, combined oral contraceptives, IUDs\n             [only hormonal], sexual abstinence or prior vasectomy) during the trial and for a\n             period of > 6 months following the last administration of trial drugs.\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breast-feeding\n\n          -  Co-medication that may interfere with study results, for example, immuno-suppressive\n             agents other than corticosteroids\n\n          -  Active infection requiring intravenous (IV) antibiotics within 7 days before\n             enrollment\n\n          -  Prior, unrelated malignancy requiring current active treatment with the exception of\n             cervical carcinoma in situ and adequately treated basal cell or squamous cell\n             carcinoma of the skin\n\n          -  Taking strong or moderate cytochrome P450 3A4 (CYP3A4) inhibitors and inducers\n\n          -  Less than 12 weeks from radiation therapy, unless progressive disease outside of the\n             radiation field or progression on 2 consecutive scans or histopathologic confirmation\n\n          -  Treated with immunotherapeutic agents or vaccines within 4 weeks before enrollment or\n             have not recovered from the toxic effects of such cancer therapy\n\n          -  Treated with alkylating agents within 4 weeks before enrollment or treated with daily\n             or metronomic chemotherapy within 1 week before enrollment, unless the patient has\n             recovered from the expected toxic effects of such cancer therapy\n\n          -  Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment or has\n             not recovered from the toxic effects of such cancer therapy\n\n          -  Current, recent (within 4 weeks of the first infusion of this study), or planned\n             participation in an experimental drug study\n\n        Vascular endothelial growth factor (VEGF) Inhibitor-Specific Exclusion Criteria are:\n\n          -  Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg\n             and/or diastolic blood pressure > 100 mmHg) within 28 days of first study treatment\n\n          -  Prior history of hypertensive crisis, hypertensive encephalopathy, reverse posterior\n             leukoencephalopathy syndrome (RPLS)\n\n          -  Prior history of gastrointestinal perforation or abscess\n\n          -  Clinically significant (active) cardiovascular disease, for example cerebrovascular\n             accidents \u2264 6 months prior to study enrollment, myocardial infarction \u2264 6 months\n             prior to study enrollment, unstable angina, New York Heart Association (NYHA) Grade 2\n             or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled\n             by medication or potentially interfering with protocol treatment\n\n          -  History or evidence upon physical/neurological examination of central nervous system\n             disease (for example, seizures) unrelated to cancer unless adequately controlled by\n             medication or potentially interfering with protocol treatment\n\n          -  Significant vascular disease (for example, aortic aneurysm requiring surgical repair\n             or recent arterial thrombosis) within 6 months prior to start of study treatment\n\n          -  History of pulmonary hemorrhage/hemoptysis \u2265 grade 2 (defined as \u2265 2.5 mL bright red\n             blood per episode) within 1 month of first study treatment\n\n          -  History or evidence of inherited bleeding diathesis or significant coagulopathy at\n             risk of bleeding (in the absence of therapeutic anticoagulation)\n\n          -  Current or recent (within 10 days of study enrollment) use of aspirin (> 325 mg/day),\n             clopidogrel (> 75 mg/day) or equivalent.  Prophylactic or therapeutic low molecular\n             weight heparin (LMWH) is allowed.\n\n          -  Surgical procedure (including open biopsy, surgical resection, wound revision, or any\n             other major surgery involving entry into a body cavity) or significant traumatic\n             injury within 28 days prior to  first study treatment, or anticipation of need for\n             major surgical procedure during the course of the study\n\n          -  Minor surgical procedure, for example, stereotactic biopsy, within 7 days of first\n             study treatment; placement of a vascular access device, within 2 days of first study\n             treatment\n\n          -  History of intracranial abscess within 6 months prior to first study treatment\n\n          -  History of active gastrointestinal bleeding within 6 months prior to first study\n             treatment\n\n          -  Serious, non-healing wound, active ulcer, or untreated bone fracture\n\n          -  Known hypersensitivity to any component of bevacizumab or CTO"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954030", 
            "org_study_id": "Pro00044274"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CTO and Bevacizumab (Phase 1)", 
                    "CTO and Bevacizumab (Phase 2)"
                ], 
                "intervention_name": "CTO and Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CTO", 
                    "Carboxyamidotriazole Orotate", 
                    "Bevacizumab", 
                    "Avastin"
                ]
            }, 
            {
                "arm_group_label": "Phase 2: CTO alone (Phase 2)", 
                "intervention_name": "CTO alone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CTO", 
                    "Carboxyamidotriazole Orotate"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboxyamido-triazole", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carboxyamidotriazole Orotate", 
            "CTO", 
            "Bevacizumab", 
            "Avastin", 
            "Malignant Glioma", 
            "Pro00044274", 
            "Ranjan", 
            "Duke", 
            "The Preston Robert Tisch Brain Tumor Center"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "description": "The Preston Robert Tisch Brain Tumor Center at Duke", 
            "url": "http://www.cancer.duke.edu/btc/"
        }, 
        "location": {
            "contact": {
                "email": "tulika.ranjan@duke.edu", 
                "last_name": "Tulika Ranjan, MD", 
                "phone": "919-681-4047"
            }, 
            "contact_backup": {
                "email": "shelley.keatts@dm.duke.edu", 
                "last_name": "Shelley Dutton", 
                "phone": "(919) 668-0673"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "The Preston Robert Tisch Brain Tumor Center at Duke"
            }, 
            "investigator": {
                "last_name": "Tulika Ranjan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure", 
        "overall_contact": {
            "email": "tulika.ranjan@duke.edu", 
            "last_name": "Tulika Ranjan, MD", 
            "phone": "(919) 681-4047"
        }, 
        "overall_contact_backup": {
            "email": "shelley.keatts@dm.duke.edu", 
            "last_name": "Shelley Dutton", 
            "phone": "(919) 668-0673"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Tulika Ranjan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A standard \"3+3\" design to determine the MTD of CTO in combination with bevacizumab.  Subjects will be administered CTO orally on a continuous daily dosing schedule, while subjects will receive bevacizumab (10 mg/kg) every 2 weeks. Cohorts of 3-6 subjects will accrue at each dose level of CTO, beginning with 225 mg/m2, until MTD is defined. The MTD is the highest dose level at which \u2264 1 out of 6 experienced a dose limiting toxicity (DLT).", 
                "measure": "Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of bevacizumab", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Percentage of participants surviving six months from start of study treatment without progression of disease.  Progression-free survival (PFS) was defined as the time from start of study treatment to the date of the first documented progression according to the Response Assessment in Neuro-Oncology (RANO) criteria, or to death due to any cause.", 
                "measure": "Phase 2: Percentage of subjects who remain alive and progression-free at 6 months", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954030"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "Tulika Ranjan", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine:\nNon-hematologic:\nNausea/vomiting of Grade 3 or greater despite maximal antiemetic therapy\nDiarrhea of Grade 3 or greater despite maximal antidiarrheal therapy\nAny other Grade 3 or 4 non-hematologic toxicity\nHematologic:\nAny Grade 4 neutropenia\nGrade 3 neutropenia associated with fever of any duration or where significant sepsis results\nGrade 4 thrombocytopenia", 
                "measure": "Phase 1:  Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "All toxicities will be collected using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to CTO or lomustine:\nNon-hematologic:\nNausea/vomiting of Grade 3 or greater despite maximal antiemetic therapy\nDiarrhea of Grade 3 or greater despite maximal antidiarrheal therapy\nAny other Grade 3 or 4 non-hematologic toxicity\nHematologic:\nAny Grade 4 neutropenia\nGrade 3 neutropenia associated with fever of any duration or where significant sepsis results\nGrade 4 thrombocytopenia", 
                "measure": "Phase 2: Percentage of subjects who experience a dose-limiting toxicity (DLT) during any cycle of protocol treatment", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time in months from start of study treatment to date of death due to any cause.  Patients alive as of the last follow-up will have OS censored at the last follow-up date.  Median OS will be estimated using a Kaplan-Meier curve.", 
                "measure": "Phase 2: Median Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Percentage of participants surviving 6 and 12 months from start of study treatment. OS is defined as time from start of study treatment to the date of death due to any cause.", 
                "measure": "Phase 2: 6 and 12 month Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Response is based on Response Assessment in Neuro-Oncology (RANO) criteria as determined by investigator assessment. A confirmation of response was not required. Complete Response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks.", 
                "measure": "Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time in months from start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause.  Patients alive who had not progressed as of the last follow-up will have PFS censored at the last follow-up date.  Median PFS will be estimated using a Kaplan-Meier curve.", 
                "measure": "Phase 2: Median PFS", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Percentage of participants surviving six months from the start of study treatment without progression of disease.  PFS is defined as the time from the date of study treatment initiation to the date of the first documented progression according to the RANO criteria, or to death due to any cause.", 
                "measure": "Phase 2: 12 month PFS", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Tactical Therapeutics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tulika Ranjan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}